A tougher Food and Drug Administration approval process and increasingly cost-conscious hospitals are factors pushing medical suppliers and devicemakers to pursue buybacks, dividends or acquisitions to appease shareholders in the wake of slow sales growth, according to a Moody's Investors Service...
FULL STORY »